pegaptanib: Clinical Trials

9 trials of pegaptanib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 1 unknown, 1 withdrawn. 9 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 7, Unknown 1, Withdrawn 1
Phase 23Completed 3

Follow pegaptanib: new trials by email Literature Review of pegaptanib trials Research Report on pegaptanib

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy
Macugen, Sham - Proliferative Diabetic Retinopathy
Phase 3WithdrawnGreater Houston Retina Research2012-04-012014-03-05
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
pegaptanib sodium - Anti- VGF Inhibitor, Diabetic Macular Edema
Phase 3CompletedPfizer462011-01-012013-09-06
A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema
pegaptanib sodium, sham injection - Macular Edema, Diabetic Mellitus
Phase 3CompletedPfizer2432010-05-012013-08-23
Subretinal MacugenĀ® for Neovascular Age-Related Macular Degeneration
Pegaptanib (MacugenĀ®) - Age-related Macular Degeneration
Phase 3UnknownKlinikum Ludwigshafen102008-11-012011-09-27
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.
Standard of Care, Macugen - Macular Edema Associated With Diabetes Mellitus
Phase 2 / Phase 3CompletedPfizer3172005-09-012018-11-16
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide - Macular Degeneration, Choroidal Neovascularization
Phase 3CompletedNovartis Pharmaceuticals1112005-09-012016-03-31
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
pegaptanib sodium - Macular Degeneration
Phase 3CompletedPfizer902004-07-012007-05-07
Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
pegaptanib sodium (Macugen) - Age-Related Macular Degeneration
Phase 2 / Phase 3CompletedEyetech Pharmaceuticals1252002-11-012006-05-03
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
Pegaptanib sodium - Age-Related Macular Degeneration
Phase 2 / Phase 3CompletedEyetech Pharmaceuticals5402001-05-012006-05-04

Conditions studied

Macular Degeneration (5)  ·  Choroidal Neovascularization (1)  ·  Diabetic Retinopathy (1)  ·  Macular Edema (1)  ·  Retinal Diseases (1)  ·  Vitreous Hemorrhage (1)

Sponsors

Pfizer (4)  ·  Eyetech Pharmaceuticals (2)  ·  Greater Houston Retina Research (1)  ·  Klinikum Ludwigshafen (1)  ·  Novartis Pharmaceuticals (1)

Countries

United States (3)  ·  Germany (2)  ·  Japan (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Austria (1)  ·  Brazil (1)  ·  Canada (1)  ·  Colombia (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Finland (1)  ·  France (1)  ·  Greece (1)  ·  India (1)

Top investigators

James C Major, MD (1)  ·  Lars-Olof Hattenbach, MD (1)

Results publications

PMID 21896838, PMID 24997182, PMID 25187694, PMID 37260074